Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr.,A Weissferdt,CH Leung,HY Lin,A Pataer, MCB Godoy,BW Carter,L Federico,A Reuben, MAW Khan,H Dejima,A Francisco-Cruz,ER Parra, LM Solis,J Fujimoto,HT Tran,N Kalhor,FV Fossella,FE Mott,AS Tsao,G Blumenschein Jr.,X Le,J Zhang,F Skoulidis,JM Kurie,M Altan,C Lu,BS Glisson,LA Byers,YY Elamin,RJ Mehran,DC Rice,GL Walsh,WL Hofstetter,JA Roth,MB Antonoff,H Kadara,C Haymaker,C Bernatchez,NJ Ajami,RR Jenq,P Sharma,JP Allison,A Futreal,JA Wargo,II Wistuba,SG Swisher,JJ Lee,DL Gibbons,AA Vaporciyan,JV Heymach,B Sepesi immuneACCESS
Key words
neoadjuvant nivolumab,cell lung cancer,lung cancer,non-small
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper